Diagnostic criteria for polymyositis and dermatomyositis [3]

Lancet

Volumn 362, Issue 9397, 2003, Pages 1762-1763

  Miller, Frederick W ^a   Rider, Lisa G ^a   Plotz, Paul H ^b   Isenberg, David A ^c   Oddis, Chester V ^d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MUSCLE ENZYME; PREDNISONE;

CLINICAL TRIAL; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LETTER; MUSCLE BIOPSY; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STANDARDIZATION; TISSUE LEVEL; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 0345414646     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14862-3     Document Type: Letter

References (3)

1. M Dalakas H Hohlfeld Polymyositis and dermatomyositis Lancet 362 2003 971 982
2. A Bohan JB Peter Polymyositis and dermatomyositis N Engl J Med 292 1975 344 347
3. IN Targoff FW Miller TA Medsger CV Oddis Classification criteria for the idiopathic inflammatory myopathies, Curr Opin Rheumatol 9 1997 527 536